<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33009713</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2328-9503</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of clinical and translational neurology</Title>
          <ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.</ArticleTitle>
        <Pagination>
          <StartPage>2231</StartPage>
          <EndPage>2242</EndPage>
          <MedlinePgn>2231-2242</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51212</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Identify the subcellular location and potential binding partners of two cerebellar degeneration-related proteins, CDR2L and CDR2, associated with anti-Yo-mediated paraneoplastic cerebellar degeneration.</AbstractText>
          <AbstractText Label="METHODS">Cancer cells, rat Purkinje neuron cultures, and human cerebellar sections were exposed to cerebrospinal fluid and serum from patients with paraneoplastic cerebellar degeneration with Yo antibodies and with several antibodies against CDR2L and CDR2. We used mass spectrometry-based proteomics, super-resolution microscopy, proximity ligation assay, and co-immunoprecipitation to verify the antibodies and to identify potential binding partners.</AbstractText>
          <AbstractText Label="RESULTS">We confirmed the CDR2L specificity of Yo antibodies by mass spectrometry-based proteomics and found that CDR2L localized to the cytoplasm and CDR2 to the nucleus. CDR2L co-localized with the 40S ribosomal protein S6, while CDR2 co-localized with the nuclear speckle proteins SON, eukaryotic initiation factor 4A-III, and serine/arginine-rich splicing factor 2.</AbstractText>
          <AbstractText Label="INTERPRETATION">We showed that Yo antibodies specifically bind to CDR2L in Purkinje neurons of PCD patients where they potentially interfere with the function of the ribosomal machinery resulting in disrupted mRNA translation and/or protein synthesis. Our findings demonstrating that CDR2L interacts with ribosomal proteins and CDR2 with nuclear speckle proteins is an important step toward understanding PCD pathogenesis.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herdlevaer</LastName>
            <ForeName>Ida</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4146-7606</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kråkenes</LastName>
            <ForeName>Torbjørn</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-4031-5360</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schubert</LastName>
            <ForeName>Manja</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3592-2470</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedeler</LastName>
            <ForeName>Christian A</ForeName>
            <Initials>CA</Initials>
            <Identifier Source="ORCID">0000-0002-0993-8906</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departments of Neurology and Clinical Medicine, Neuro-SysMed - Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Clin Transl Neurol</MedlineTA>
        <NlmUniqueID>101623278</NlmUniqueID>
        <ISSNLinking>2328-9503</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095184">CDR2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000599484">CDR2L antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="Y">Autoantigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="Y">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003593" MajorTopicYN="Y">Cytoplasm</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011689" MajorTopicYN="Y">Purkinje Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interest to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33009713</ArticleId>
        <ArticleId IdType="pmc">PMC7664253</ArticleId>
        <ArticleId IdType="doi">10.1002/acn3.51212</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti‐Yo antibody‐positive patients. Neurol.
1992;42:1931–1937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European J Neurol.
2006;13:682–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16834698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raspotnig M, Haugen M, Thorsteinsdottir M, et al. Cerebellar degeneration‐related proteins 2 and 2‐like are present in ovarian cancer in patients with and without Yo antibodies. Cancer immunol immunother
2017;66:1463–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Darnell RB, Posner JB. Paraneoplastic Syndromes Involving the Nervous. System.
2003;349(16):1543–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry
2004;75 Suppl 2(Suppl 2):ii43‐ii50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1765657</ArticleId>
            <ArticleId IdType="pubmed">15146039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichler TW, Totland C, Haugen M, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PloS one.
2013;8(6):e66002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3688866</ArticleId>
            <ArticleId IdType="pubmed">23823982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krakenes T, Herdlevaer I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L is the major yo antibody target in paraneoplastic cerebellar degeneration. Annals of Neurol
2019;86:316–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31148214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol
2014;128(6):835–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor‐specific killer cells in paraneoplastic cerebellar degeneration. Nature Med
1998;4:1321–1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti‐Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol
2010;69:997–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2959164</ArticleId>
            <ArticleId IdType="pubmed">20838245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sato S, Inuzuka T, Nakano R, et al. Antibody to a zinc finger protein in a patient with paraneoplastic cerebellar degeneration. Biochem Biophys Res Commun
1991;178:198–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1712585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A Post‐transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to Immune Privileged Tissues. J Neurosci.
1997;17:1406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793730</ArticleId>
            <ArticleId IdType="pubmed">9006982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Totland C, Aarskog NK, Eichler TW, et al. CDR2 antigen and Yo antibodies. Cancer Immunology Immunother
2011;60:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Small M, Treilleux I, Couillault C, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol
2018;135:569–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29299667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakai K, Shirakawa T, Li Y, Kitagawa Y, Hirose G. Interaction of a paraneoplastic cerebellar degeneration‐associated neuronal protein with the nuclear helix‐loop‐helix leucine zipper protein MRG X. Mol Cell Neurosci
2002;19:477–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11988016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down‐regulates c‐Myc function: implications for neuronal and tumor cell survival. Genes Dev
1999;13:2087–2097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fathallah‐Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM. Cloning of a leucine‐zipper protein recognized by the sera of patients with antibody‐associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA
1991;88:3451–3454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC51465</ArticleId>
            <ArticleId IdType="pubmed">2014264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y. PKN interacts with a paraneoplastic cerebellar degeneration‐associated antigen, which is a potential transcription factor. Exp Cell Res
1998;241:363–372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9637778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G. Effect of a paraneoplastic cerebellar degeneration‐associated neural protein on B‐myb promoter activity. Neurobiol Dis
2004;15:529–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15056460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Uggerud IM, Krakenes T, Hirai H, Vedeler CA, Schubert M. Development and optimization of a high‐throughput 3D rat Purkinje neuron culture. bioRxiv.
2020;105858.</Citation>
        </Reference>
        <Reference>
          <Citation>
Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix‐assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Analytical Chem
2003;75:663–670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12585499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Olsen JV, de Godoy LM, Li G, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C‐trap. Mol Cell Proteomics
2005;4:2010–2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16249172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality‐controlled protein‐protein association networks, made broadly accessible. Nucleic Acids Res
2017;45(D1):D362–d8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210637</ArticleId>
            <ArticleId IdType="pubmed">27924014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein‐protein association networks with increased coverage, supporting functional discovery in genome‐wide experimental datasets. Nucleic Acids Res
2019;47(D1):D607–d13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand
2009;120:64–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune‐paraneoplastic‐cerebellar‐degeneration‐Ultrastructural‐localization‐of‐antibody‐binding‐sites‐in‐purkinje‐cells. Neurology
1988;38:1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3045692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hida C, Tsukamoto T, Awano H, Yamamoto T. Ultrastructural localization of anti‐Purkinje cell antibody‐binding sites in paraneoplastic cerebellar degeneration. Arch Neurol
1994;51:555–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8198465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mukai H, Miyahara M, Sunakawa H, et al. Translocation of PKN from the cytosol to the nucleus induced by stresses. Proc Natl Acad Sci USA.
1996;93(19):10195–10199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC38360</ArticleId>
            <ArticleId IdType="pubmed">8816775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O’Donovan B, Mandel‐Brehm C, Vazquez SE, et al. High resolution epitope mapping of anti‐Hu and anti‐Yo autoimmunity by programmable phage display. Brain Communications.
2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7425417</ArticleId>
            <ArticleId IdType="pubmed">32954318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fei J, Jadaliha M, Harmon TS, et al. Quantitative analysis of multilayer organization of proteins and RNA in nuclear speckles at super resolution. J Cell Sci
2017;130:4180–4192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5769577</ArticleId>
            <ArticleId IdType="pubmed">29133588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA. Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell.
2010;21:650–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820428</ArticleId>
            <ArticleId IdType="pubmed">20053686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin S, Coutinho‐Mansfield G, Wang D, Pandit S, Fu X‐D. The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct Mol Biol
2008;15:819–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2574591</ArticleId>
            <ArticleId IdType="pubmed">18641664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahn E‐Y, DeKelver Russell C, Lo M‐C, et al. son controls cell‐cycle progression by coordinated regulation of RNA Splicing. Molecular Cell
2011;42:185–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137374</ArticleId>
            <ArticleId IdType="pubmed">21504830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan CC, Dostie J, Diem MD, et al. eIF4A3 is a novel component of the exon junction complex. RNA.
2004;10:200–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1370532</ArticleId>
            <ArticleId IdType="pubmed">14730019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh G, Kucukural A, Cenik C, et al. The cellular EJC interactome reveals higher‐order mRNP structure and an EJC‐SR protein nexus. Cell.
2012;151:750–764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3522173</ArticleId>
            <ArticleId IdType="pubmed">23084401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol
2018;217:51–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5748993</ArticleId>
            <ArticleId IdType="pubmed">29127110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aitken CE, Lorsch JR. A mechanistic overview of translation initiation in eukaryotes. Nat Struct Mol Biol
2012;19:568–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22664984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lehmkuhl EM, Zarnescu DC. Lost in Translation: Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases. Adv Neurobiol
2018;20:283–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6530776</ArticleId>
            <ArticleId IdType="pubmed">29916024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci
2006;31:342–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16679021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Biever A, Valjent E, Puighermanal E. Ribosomal protein S6 phosphorylation in the nervous system. From Regulation to Function. Front Mol Neurosci
2015;8:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679984</ArticleId>
            <ArticleId IdType="pubmed">26733799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Puighermanal E, Biever A, Pascoli V, et al. Ribosomal protein S6 phosphorylation is involved in novelty‐induced locomotion, synaptic plasticity and mRNA translation. Front Mol Neurosci
2017;10:419
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5742586</ArticleId>
            <ArticleId IdType="pubmed">29311811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rogers GW Jr, Richter NJ, Lima WF, Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem
2001;276:30914–30922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11418588</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33009713</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2328-9503</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of clinical and translational neurology</Title>
          <ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.</ArticleTitle>
        <Pagination>
          <StartPage>2231</StartPage>
          <EndPage>2242</EndPage>
          <MedlinePgn>2231-2242</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51212</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Identify the subcellular location and potential binding partners of two cerebellar degeneration-related proteins, CDR2L and CDR2, associated with anti-Yo-mediated paraneoplastic cerebellar degeneration.</AbstractText>
          <AbstractText Label="METHODS">Cancer cells, rat Purkinje neuron cultures, and human cerebellar sections were exposed to cerebrospinal fluid and serum from patients with paraneoplastic cerebellar degeneration with Yo antibodies and with several antibodies against CDR2L and CDR2. We used mass spectrometry-based proteomics, super-resolution microscopy, proximity ligation assay, and co-immunoprecipitation to verify the antibodies and to identify potential binding partners.</AbstractText>
          <AbstractText Label="RESULTS">We confirmed the CDR2L specificity of Yo antibodies by mass spectrometry-based proteomics and found that CDR2L localized to the cytoplasm and CDR2 to the nucleus. CDR2L co-localized with the 40S ribosomal protein S6, while CDR2 co-localized with the nuclear speckle proteins SON, eukaryotic initiation factor 4A-III, and serine/arginine-rich splicing factor 2.</AbstractText>
          <AbstractText Label="INTERPRETATION">We showed that Yo antibodies specifically bind to CDR2L in Purkinje neurons of PCD patients where they potentially interfere with the function of the ribosomal machinery resulting in disrupted mRNA translation and/or protein synthesis. Our findings demonstrating that CDR2L interacts with ribosomal proteins and CDR2 with nuclear speckle proteins is an important step toward understanding PCD pathogenesis.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herdlevaer</LastName>
            <ForeName>Ida</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4146-7606</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kråkenes</LastName>
            <ForeName>Torbjørn</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-4031-5360</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schubert</LastName>
            <ForeName>Manja</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3592-2470</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedeler</LastName>
            <ForeName>Christian A</ForeName>
            <Initials>CA</Initials>
            <Identifier Source="ORCID">0000-0002-0993-8906</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departments of Neurology and Clinical Medicine, Neuro-SysMed - Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Clin Transl Neurol</MedlineTA>
        <NlmUniqueID>101623278</NlmUniqueID>
        <ISSNLinking>2328-9503</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095184">CDR2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000599484">CDR2L antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="Y">Autoantigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="Y">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003593" MajorTopicYN="Y">Cytoplasm</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011689" MajorTopicYN="Y">Purkinje Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interest to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33009713</ArticleId>
        <ArticleId IdType="pmc">PMC7664253</ArticleId>
        <ArticleId IdType="doi">10.1002/acn3.51212</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti‐Yo antibody‐positive patients. Neurol.
1992;42:1931–1937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European J Neurol.
2006;13:682–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16834698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raspotnig M, Haugen M, Thorsteinsdottir M, et al. Cerebellar degeneration‐related proteins 2 and 2‐like are present in ovarian cancer in patients with and without Yo antibodies. Cancer immunol immunother
2017;66:1463–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Darnell RB, Posner JB. Paraneoplastic Syndromes Involving the Nervous. System.
2003;349(16):1543–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry
2004;75 Suppl 2(Suppl 2):ii43‐ii50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1765657</ArticleId>
            <ArticleId IdType="pubmed">15146039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichler TW, Totland C, Haugen M, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PloS one.
2013;8(6):e66002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3688866</ArticleId>
            <ArticleId IdType="pubmed">23823982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krakenes T, Herdlevaer I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L is the major yo antibody target in paraneoplastic cerebellar degeneration. Annals of Neurol
2019;86:316–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31148214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol
2014;128(6):835–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor‐specific killer cells in paraneoplastic cerebellar degeneration. Nature Med
1998;4:1321–1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti‐Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol
2010;69:997–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2959164</ArticleId>
            <ArticleId IdType="pubmed">20838245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sato S, Inuzuka T, Nakano R, et al. Antibody to a zinc finger protein in a patient with paraneoplastic cerebellar degeneration. Biochem Biophys Res Commun
1991;178:198–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1712585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A Post‐transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to Immune Privileged Tissues. J Neurosci.
1997;17:1406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793730</ArticleId>
            <ArticleId IdType="pubmed">9006982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Totland C, Aarskog NK, Eichler TW, et al. CDR2 antigen and Yo antibodies. Cancer Immunology Immunother
2011;60:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Small M, Treilleux I, Couillault C, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol
2018;135:569–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29299667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakai K, Shirakawa T, Li Y, Kitagawa Y, Hirose G. Interaction of a paraneoplastic cerebellar degeneration‐associated neuronal protein with the nuclear helix‐loop‐helix leucine zipper protein MRG X. Mol Cell Neurosci
2002;19:477–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11988016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down‐regulates c‐Myc function: implications for neuronal and tumor cell survival. Genes Dev
1999;13:2087–2097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fathallah‐Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM. Cloning of a leucine‐zipper protein recognized by the sera of patients with antibody‐associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA
1991;88:3451–3454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC51465</ArticleId>
            <ArticleId IdType="pubmed">2014264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y. PKN interacts with a paraneoplastic cerebellar degeneration‐associated antigen, which is a potential transcription factor. Exp Cell Res
1998;241:363–372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9637778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G. Effect of a paraneoplastic cerebellar degeneration‐associated neural protein on B‐myb promoter activity. Neurobiol Dis
2004;15:529–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15056460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Uggerud IM, Krakenes T, Hirai H, Vedeler CA, Schubert M. Development and optimization of a high‐throughput 3D rat Purkinje neuron culture. bioRxiv.
2020;105858.</Citation>
        </Reference>
        <Reference>
          <Citation>
Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix‐assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Analytical Chem
2003;75:663–670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12585499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Olsen JV, de Godoy LM, Li G, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C‐trap. Mol Cell Proteomics
2005;4:2010–2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16249172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality‐controlled protein‐protein association networks, made broadly accessible. Nucleic Acids Res
2017;45(D1):D362–d8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210637</ArticleId>
            <ArticleId IdType="pubmed">27924014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein‐protein association networks with increased coverage, supporting functional discovery in genome‐wide experimental datasets. Nucleic Acids Res
2019;47(D1):D607–d13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand
2009;120:64–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune‐paraneoplastic‐cerebellar‐degeneration‐Ultrastructural‐localization‐of‐antibody‐binding‐sites‐in‐purkinje‐cells. Neurology
1988;38:1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3045692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hida C, Tsukamoto T, Awano H, Yamamoto T. Ultrastructural localization of anti‐Purkinje cell antibody‐binding sites in paraneoplastic cerebellar degeneration. Arch Neurol
1994;51:555–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8198465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mukai H, Miyahara M, Sunakawa H, et al. Translocation of PKN from the cytosol to the nucleus induced by stresses. Proc Natl Acad Sci USA.
1996;93(19):10195–10199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC38360</ArticleId>
            <ArticleId IdType="pubmed">8816775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O’Donovan B, Mandel‐Brehm C, Vazquez SE, et al. High resolution epitope mapping of anti‐Hu and anti‐Yo autoimmunity by programmable phage display. Brain Communications.
2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7425417</ArticleId>
            <ArticleId IdType="pubmed">32954318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fei J, Jadaliha M, Harmon TS, et al. Quantitative analysis of multilayer organization of proteins and RNA in nuclear speckles at super resolution. J Cell Sci
2017;130:4180–4192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5769577</ArticleId>
            <ArticleId IdType="pubmed">29133588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA. Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell.
2010;21:650–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820428</ArticleId>
            <ArticleId IdType="pubmed">20053686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin S, Coutinho‐Mansfield G, Wang D, Pandit S, Fu X‐D. The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct Mol Biol
2008;15:819–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2574591</ArticleId>
            <ArticleId IdType="pubmed">18641664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahn E‐Y, DeKelver Russell C, Lo M‐C, et al. son controls cell‐cycle progression by coordinated regulation of RNA Splicing. Molecular Cell
2011;42:185–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137374</ArticleId>
            <ArticleId IdType="pubmed">21504830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan CC, Dostie J, Diem MD, et al. eIF4A3 is a novel component of the exon junction complex. RNA.
2004;10:200–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1370532</ArticleId>
            <ArticleId IdType="pubmed">14730019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh G, Kucukural A, Cenik C, et al. The cellular EJC interactome reveals higher‐order mRNP structure and an EJC‐SR protein nexus. Cell.
2012;151:750–764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3522173</ArticleId>
            <ArticleId IdType="pubmed">23084401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol
2018;217:51–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5748993</ArticleId>
            <ArticleId IdType="pubmed">29127110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aitken CE, Lorsch JR. A mechanistic overview of translation initiation in eukaryotes. Nat Struct Mol Biol
2012;19:568–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22664984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lehmkuhl EM, Zarnescu DC. Lost in Translation: Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases. Adv Neurobiol
2018;20:283–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6530776</ArticleId>
            <ArticleId IdType="pubmed">29916024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci
2006;31:342–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16679021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Biever A, Valjent E, Puighermanal E. Ribosomal protein S6 phosphorylation in the nervous system. From Regulation to Function. Front Mol Neurosci
2015;8:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679984</ArticleId>
            <ArticleId IdType="pubmed">26733799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Puighermanal E, Biever A, Pascoli V, et al. Ribosomal protein S6 phosphorylation is involved in novelty‐induced locomotion, synaptic plasticity and mRNA translation. Front Mol Neurosci
2017;10:419
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5742586</ArticleId>
            <ArticleId IdType="pubmed">29311811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rogers GW Jr, Richter NJ, Lima WF, Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem
2001;276:30914–30922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11418588</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
